Lipocine Begin Period Cash Flow from 2010 to 2025

LPCN Stock  USD 3.63  0.09  2.54%   
Lipocine Begin Period Cash Flow yearly trend continues to be very stable with very little volatility. Begin Period Cash Flow is likely to drop to about 2.7 M. Begin Period Cash Flow is the amount of cash Lipocine has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2012-03-31
Previous Quarter
3.1 M
Current Value
5.6 M
Quarterly Volatility
11.9 M
 
Yuan Drop
 
Covid
Check Lipocine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipocine's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.8 M or Other Operating Expenses of 14.9 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 0.68 or Book Value Per Share of 4.22. Lipocine financial statements analysis is a perfect complement when working with Lipocine Valuation or Volatility modules.
  
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Latest Lipocine's Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of Lipocine over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Lipocine's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lipocine's overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Very volatile
   Begin Period Cash Flow   
       Timeline  

Lipocine Begin Period Cash Flow Regression Statistics

Arithmetic Mean10,675,183
Geometric Mean2,731,478
Coefficient Of Variation120.20
Mean Deviation10,113,720
Median5,377,114
Standard Deviation12,831,317
Sample Variance164.6T
Range45.2M
R-Value(0.08)
Mean Square Error175.3T
R-Squared0.01
Significance0.77
Slope(214,758)
Total Sum of Squares2469.6T

Lipocine Begin Period Cash Flow History

20252.7 M
20242.8 M
20233.1 M
2022M
202124.2 M
202014.7 M
201913.1 M

About Lipocine Financial Statements

Lipocine investors utilize fundamental indicators, such as Begin Period Cash Flow, to predict how Lipocine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Begin Period Cash Flow2.8 M2.7 M
When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.75)
Revenue Per Share
1.486
Quarterly Revenue Growth
137.519
Return On Assets
(0.15)
Return On Equity
(0.20)
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.